EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A novel, fixed‐dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30 th EADV Congress 2021

Andreas Pinter iD, Linda Stein Gold iD, Adam Reich iD, Lawrence J Green iD, Morten Praestegaard iD, Johan Selmer, April W Armstrong iD, Anne Danø, Sunil Dhawan, Jordi Galván iD, Sandra E Stallknecht iD, Paw Trebbien und 1 weitere

Journal of the European Academy of Dermatology and Venereology · 2023

DOI: 10.1111/jdv.18755 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Andreas Pinter und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Dermatologic Agents, Psoriasis, Venereology. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: Almirall, Barcelona, Spain.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Four posters about the novel, fixed‐dose calcipotriol and betamethasone dipropionate cream (CAL/BDP cream) based on Poly‐Aphron Dispersion (PAD) Technology were presented at the 30 th European Academy of Dermatology and Venereology (EADV) Congress 2021 and are summarized here. CAL/BDP cream was compared in two randomized, phase 3 trials to vehicle and active comparator (CAL/BDP gel/topical suspension [TS]) in adults with plaque psoriasis (NCT03802344 and NCT03308799). Pooled data from both trials demonstrated significant greater efficacy in favour of CAL/BDP cream for all efficacy endpoints, including PGA treatment success, mPASI, and mPASI75 compared to CAL/BDP gel/TS. CAL/BDP cream was well tolerated and comparable to CAL/BDP gel/TS with no adverse drug reactions with a frequency >1%. In the NCT03308799 study, CAL/BDP cream demonstrated a substantial improvement in the proportion of participants achieving a minimum 4‐point improvement on the peak pruritus numeric rating scale (NRS) score compared with vehicle at Weeks 1, 4 and 8. CAL/BDP cream also improved quality of life (QoL), as assessed through the Dermatology Life Quality Index (DLQI), and the EQ‐VAS at Week 8 compared with active comparator. Treatment convenience of CAL/BDP cream, as measured by the Psoriasis Treatment Convenience Scale, was superior to CAL/BDP gel/TS at all studied timepoints, including questions addressing formulation's greasiness and overall treatment satisfaction. Finally, an indirect comparison following the Bucher's method of adjusted indirect comparison and the difference‐in‐differences method was conducted to compare CAL/BDP cream and CAL/BDP foam, as both therapies have been compared to CAL/BDP gel/TS. Indirect evidence showed that treatment with CAL/BDP cream was associated with a trend for greater QoL improvement than CAL/BDP foam when DLQI improvement was assessed at the recommended treatment duration of 8 weeks for CAL/BDP cream and 4 weeks for CAL/BDP foam. CAL/BDP cream was statistically superior versus CAL/BDP foam in four out of five treatment satisfaction domains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatologic AgentsPsoriasisVenereologyAdultHumansBetamethasoneClinical Trials, Phase III as TopicDrug CombinationsEmollientsQuality of LifeTreatment OutcomeRandomized Controlled Trials as TopicCalcitriol

Substanzen

BetamethasoneDermatologic AgentsDrug CombinationsEmollientsbetamethasone-17,21-dipropionatecalcipotrieneCalcitriol

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany.
  • Dermatology Clinical Research, Henry Ford Health System, Detroit, Michigan, USA.
  • Department of Dermatology, University of Rzeszów, Rzeszów, Poland.
  • George Washington University School of Medicine, Washington, District of Columbia, USA.
  • MC2 Therapeutics, Hørsholm, Denmark.
  • Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

ORCID-Profile: Andreas Pinter, Linda Stein Gold, Adam Reich, Lawrence J Green, Morten Praestegaard, April W Armstrong, Jordi Galván, Sandra E Stallknecht, Matthias Augustin

Förderung

  • Almirall, Barcelona, Spain

Zitieren

APA

Pinter, A., Gold, L. S., Reich, A., Green, L. J., Praestegaard, M., Selmer, J., Armstrong, A. W., Danø, A., Dhawan, S., Galván, J., Stallknecht, S. E., Trebbien, P., & Augustin, M. (2023). A novel, fixed‐dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30 th EADV Congress 2021. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.18755

Vancouver

Pinter A, Gold LS, Reich A, Green LJ, Praestegaard M, Selmer J, et al. A novel, fixed‐dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30 th EADV Congress 2021. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.18755

BibTeX
@article{Pinter2023,
  author = {Pinter, Andreas and Gold, Linda Stein and Reich, Adam and Green, Lawrence J and Praestegaard, Morten and Selmer, Johan and Armstrong, April W and Danø, Anne and Dhawan, Sunil and Galván, Jordi and Stallknecht, Sandra E and Trebbien, Paw and Augustin, Matthias},
  title = {A novel, fixed‐dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30 th EADV Congress 2021},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  doi = {10.1111/jdv.18755}
}
Kostenlos starten →